Trial Profile
A Phase 3 Randomized, Double-Blind, Active-controlled Study to Evaluate the Efficacy and Safety of Lurasidone in Acutely Psychotic Patients With Schizophrenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Lurasidone (Primary) ; Quetiapine
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Bukwang Pharmaceutical
- 06 Feb 2023 Status changed from active, no longer recruiting to completed.
- 19 Jul 2022 Planned End Date changed from 1 Jun 2021 to 1 Nov 2022.
- 19 Jul 2022 Planned primary completion date changed from 1 Jan 2021 to 1 Aug 2022.